2016/02/05

Golden Biotechnology Corporation (GBC)’s new drug candidate, Antroquinonol® (trade name: Hocena®) passed the first stage of the Phase II multicenter trial on non-small cell lung cancer (NSCLC).

Both effectiveness and safety surpassed the expectations on a Phase II / Stage 1 meeting via the Data and Safety Monitoring Board (DSMB).